Nissay Asset Management Corp Japan ADV Grows Stock Holdings in STERIS plc (NYSE:STE)

Nissay Asset Management Corp Japan ADV boosted its position in STERIS plc (NYSE:STE) by 0.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 11,905 shares of the medical equipment provider’s stock after acquiring an additional 95 shares during the period. Nissay Asset Management Corp Japan ADV’s holdings in STERIS were worth $2,476,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Magnolia Capital Advisors LLC grew its stake in STERIS by 1.9% in the 4th quarter. Magnolia Capital Advisors LLC now owns 2,534 shares of the medical equipment provider’s stock worth $521,000 after acquiring an additional 48 shares during the period. Park Edge Advisors LLC grew its stake in shares of STERIS by 1.1% during the 4th quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider’s stock valued at $958,000 after buying an additional 51 shares during the period. Citizens Financial Group Inc. RI grew its stake in shares of STERIS by 5.9% during the 4th quarter. Citizens Financial Group Inc. RI now owns 975 shares of the medical equipment provider’s stock valued at $201,000 after buying an additional 54 shares during the period. Opal Wealth Advisors LLC grew its stake in shares of STERIS by 5.7% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,118 shares of the medical equipment provider’s stock valued at $230,000 after buying an additional 60 shares during the period. Finally, Sage Private Wealth Group LLC grew its stake in shares of STERIS by 4.1% during the 4th quarter. Sage Private Wealth Group LLC now owns 1,537 shares of the medical equipment provider’s stock valued at $316,000 after buying an additional 61 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Stock Performance

NYSE:STE opened at $252.12 on Friday. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $24.77 billion, a price-to-earnings ratio of 53.53 and a beta of 0.96. The firm’s fifty day simple moving average is $224.13 and its 200 day simple moving average is $219.31. STERIS plc has a twelve month low of $200.98 and a twelve month high of $252.20.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.15. The business had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.47 billion. STERIS had a net margin of 8.66% and a return on equity of 13.91%. The business’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.58 EPS. As a group, equities research analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 26th. Investors of record on Tuesday, June 10th will be issued a dividend of $0.57 per share. The ex-dividend date is Tuesday, June 10th. This represents a $2.28 annualized dividend and a dividend yield of 0.90%. STERIS’s payout ratio is 36.77%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on STE. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research note on Monday, April 7th. JMP Securities boosted their price objective on shares of STERIS from $265.00 to $280.00 and gave the company a “market outperform” rating in a research note on Friday. Stephens reissued an “overweight” rating and set a $250.00 price objective on shares of STERIS in a research note on Thursday. Finally, Piper Sandler boosted their price objective on shares of STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, STERIS currently has a consensus rating of “Moderate Buy” and an average target price of $265.00.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.